Aurora Cannabis, Canopy Growth, and Aphria Hemp struck a big win this week as a new study has been released that shows Cannabis with THC has shown to not only provide levels of pain relief for fibromyalgia pain, but has proved to show a major impact in fibromyalgia pain. Currently, the three powerhouse Cannabis companies are held back by red tape still in place by the FDA (for trademark protection and licences) and the DEA (to make a successful transition into US market). However, this study is now making the FDA and DEA adjust their industry doctrines on THC which will open the door to companies wishing to enter the US market.
A study out of the Netherlands found that,
standardised pharmaceutical-grade cannabis with a high tetrahydrocannabinol (THC) content was effective in treating the musculoskeletal pain caused by fibromyalgia.
Conducted by Leiden University Medical Centre (LUMC) in co-operation with Bedrocan International, the study involving the pharmaceutical-grade cannabis provided by the company further found “cannabis flos with only cannabidiol (CBD) did not provide the patients with relief.”
The research involved a total of 20 patients treated at four distinct moments, as well as the administration of three different cannabis products provided by Bedrocan and placebo (cannabis without the main active substances THC and CBD) by a vaporizer.
Investors can take notice that studies like these add legitimacy to emerging marijuana companies. Emerging Cannabis companies, such as CBD of Denver (CBDD) expect to benefit from the added legitimacy of CBD companies. Currently trading at a $3.5 million market valuation based on 3,903,688,107 shares outstanding CBDD is the newest CBD Company to hit the OTCPINKS. CBD of Denver has a catchy name and the Company already established its corporate offices in Denver. The Company is led by new CEO Nicholas Sprung, a serial entrepreneur who used to be CEO of a Ski Company with an ambitious vision to make CBD of Denver a leader in the booming CBD space. CBDD is quickly attracting a fast growing shareholder base, as seen by above average trading volume in this sector of the PPS spectrum.
All subjects were exposed to externally inflicted pain by applying increasing pressure, reports the company, a producer of legal medicinal cannabis that provides standardised medical cannabis capable of being used as an active pharmaceutical ingredient (API) to the Dutch government. With two of the company products, “patients experienced significantly less pressure pain compared to the placebo,” the company statement notes.
“The outcome is very important for patients who suffer from fibromyalgia. Now we have the serious clinical evidence that medical doctors are asking for when prescribing our products and that health insurance companies want to have, to legitimize reimbursement,”
What does this mean for the main players in the THC industry?
Earlier this year, Canopy reached a deal with Constellation Brands (STZ) for a $4 billion investment, giving it a massive infusion of capital. And last month, Canopy Growth agreed to acquire Ebbu, a hemp research and development company. Canopy, at that time, also said that Ebbu’s advancements on R&D “apply directly to Canopy Growth’s hemp and THC-rich cannabis genetic breeding program and its cannabis-infused beverage capabilities.”
From this, many analysts are suggesting that the marijuana and hemp powerhouses are posturing to trademark their CBD products now that Donald Trump has signed the bill. One emerging Cannabis company has possibly found a way past this. Profile Solutions Inc (OTC:PSIQ)instead has purchased one of the most well known brands in the Cannabis industry, that of Cheech & Chong Product Line. While these are currently only mens grooming products, they are already trade marked. Now, when their large scale growing operation goes operational (See Here), they will only have to put the CBD products under the banner of Cheech and Chong, and thus it would be trade marked.
Aphria announced Wednesday it has struck a deal with Insumos Medicos to provide the Paraguayan pharmaceutical company with medical-grade cannabis, the first such deal in the country. Paraguay will become Aphria’s third market in Latin America, following Argentina and Colombia, which follows PSIQ’s expansion into Latin America.